Streetbeat News

Analyst Ratings

ITRI

Itron (NASDAQ:ITRI) has been analyzed by 6 analysts, showing a range of opinions. The average 12-month price target is $77.0, with a high of $91.00 and a low of $68.00, marking a 7.69% increase from the previous target of $71.50. Analysts from firms including Oppenheimer, Piper Sandler, JP Morgan, Roth MKM, and Canaccord Genuity have provided ratings and adjusted price targets. Itron's financial performance shows a 33.24% revenue growth, a net margin of 7.16%, an ROE of 3.29%, an ROA of 1.6%, and a low debt-to-equity ratio of 0.39.

Portfolio Pulse from Benzinga Insights

January 19, 2024 | 3:00 pm

WTFC

Wintrust Financial Corporation (NASDAQ: WTFC) was analyzed by 5 analysts, showing a shift towards a more bullish stance over the last quarter. The average 12-month price target is now $106.2, up 6.55% from the previous $99.67. Analysts from firms including Keefe, Bruyette & Woods, RBC Capital, Wedbush, Truist Securities, and Citigroup have raised or maintained their price targets and ratings, indicating a positive outlook for WTFC. However, the company faces challenges with a slight revenue decline, below-average net margin, ROE, and ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 19, 2024 | 3:00 pm

RARE

Ultragenyx Pharmaceutical (NASDAQ:RARE) has been evaluated by four analysts in the past three months, with all four maintaining a 'Somewhat Bullish' stance. The average 12-month price target for RARE is now $100.0, down 11.11% from the previous average, with a high estimate of $130.00 and a low of $72.00. Analysts from Cantor Fitzgerald, Wells Fargo, Morgan Stanley, and Piper Sandler have provided ratings and adjusted price targets, reflecting their views on the company's market position and financial performance. Ultragenyx Pharmaceutical is a biopharmaceutical company focusing on rare and ultra-rare diseases, with products like Crysvita, Dojolvi, and Mepsevii. Financially, the company has a high market capitalization and a positive revenue growth rate of 8.1%, but faces challenges with a net margin of -162.82%, ROE of -198.64%, ROA of -12.52%, and a high debt-to-equity ratio of 1.47.

Portfolio Pulse from Benzinga Insights

January 19, 2024 | 3:00 pm

AKAM

Analysts have provided mixed ratings for Akamai Technologies (NASDAQ:AKAM) with 4 somewhat bullish, 2 indifferent, and 1 somewhat bearish ratings. The average 12-month price target for AKAM has been raised to $121.29, up from $107.00. Key analysts from firms like Keybanc, Susquehanna, and Morgan Stanley have adjusted their price targets and ratings, reflecting a response to market conditions and company performance. Akamai operates a significant CDN and security business, showing strong financial health with a market cap above industry average, a net margin of 16.63%, and an ROE of 3.73%. However, its revenue growth rate of 9.48% is below the IT sector average.

Portfolio Pulse from Benzinga Insights

January 19, 2024 | 3:00 pm

GLOB

Keybanc analyst Thomas Blakey has maintained an Overweight rating on Globant (NYSE:GLOB) and increased the price target from $218 to $266.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 2:59 pm

DBX

Keybanc analyst Thomas Blakey has maintained an Overweight rating on Dropbox (NASDAQ:DBX) and increased the price target from $32 to $37, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 2:57 pm

BAND

Keybanc analyst Thomas Blakey has maintained an Overweight rating on Bandwidth Inc. (NASDAQ:BAND) and increased the price target from $14 to $16.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 2:54 pm

AKAM

Keybanc analyst Brandon Nispel has maintained an Overweight rating on Akamai Technologies (NASDAQ:AKAM) and increased the price target from $134 to $138.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 2:51 pm

AMD

HPE

ISRG

JNPR

META

NVDA

PANW

AI stocks have been leading gains in the S&P 500 index in January, with Juniper Networks, Nvidia, and Palo Alto Networks among the top performers. Juniper Networks received a $14 billion takeover offer from Hewlett Packard Enterprise, Nvidia continued its strong performance with a 15% gain in January, and Palo Alto Networks saw a 14% increase. Nvidia's technology and market share in AI GPUs, including a large purchase by Meta Platforms, positions it well for 2024. Palo Alto Networks is also favored by analysts for its role in cybersecurity against AI-powered threats. Other notable companies include AMD with a 10.3% gain and Intuitive Surgical, also up by 10.3%, both benefiting from the AI trend.

Portfolio Pulse from Neil Dennis

January 19, 2024 | 2:37 pm

RARE

Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) with a maintained price target of $114.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 2:33 pm